Please login to the form below
Patent exclusivity
This page shows the latest Patent exclusivity news and features for those working in and with pharma, biotech and healthcare.
Amarin shares tumble following Vascepa patent loss
The patent ruling only applies to Vascepa’s US patent exclusivity, with Amarin clarifying that its patents elsewhere in the world still stand.
Latest news
-
UPDATED: Gilead drops remdesivir’s orphan drug designation
Gilead had maintained that at the time that it had filed for the designation – which awards companies with patent exclusivity for seven years – the coronavirus outbreak was nowhere near the level ... Along with patent exclusivity, orphan drug
-
China’s BrightGene successfully copies Gilead’s coronavirus hopeful remdesivir
Raises concerns over patent exclusivity in the country. UPDATED 5 MARCH 2020: BrightGene has since been censured by the Shanghai Stock Exchange (SSE) for making misleading claims and disclosing inaccurate information ... The news reflects a larger issue
-
Biologic patent exclusivity scrapped in new US trade deal
The negotiations between the US, Mexico and Canada have reached an agreement to scrap patent exclusivity for biologics, meaning that each country can determine its own rules. ... In the past, the US has pushed to have its exclusivity rules applied to
-
AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER
That initial finding damaged AbbVie’s hopes of growing sales of Rinvoq to offset the anticipated loss of Humira revenues to biosimilar competitors when it loses its patent exclusivity.
-
Amgen snaps up Celgene’s Otezla for $13.4bn
This includes Enbrel (boosted earlier this month by a successful defence of its US patent) and Amgevita, its Humira biosimilar, which is approved and already available in Europe and approved ahead ... The drug has patent exclusivity through at least 2028
More from news
Approximately 1 fully matching, plus 57 partially matching documents found.
Latest Intelligence
-
The impact of COVID-19 on clinical trials
Delays in clinical trials will also likely translate into delays in launch timelines, which may result in shorter periods of patent exclusivity post-launch and lower revenue forecasts.
-
Interview: Trevor Smith, Takeda
Major products were about to lose, or had just lost, their patent exclusivity.”. ... For Nycomed this meant loss of exclusivity (LOE) on its blockbuster gastroinestinal drug pantoprazole and the consequent need to reorganise its business.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Three strategies for managing loss of exclusivity successfully
Price decay after loss of brand exclusivity”. These are just three headlines that come up when you Google “drug patent expiry”. It’s no wonder “loss of exclusivity (LOE)” or “the ... Loss of exclusivity (LOE) is a natural milestone in a
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Lead Copywriter
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Medical Editor
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
-
Healthcare Account Director
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- Sinovac’s COVID-19 vaccine appears safe in older adults
- New study identifies drugs that are safe to use in COVID-19 treatment
- Pfizer introduces new logo in a ‘shift from commerce to science’
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Valid Insight
Valid Insight is an award-winning pharmaceutical global market access consultancy....
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
